Establishing an Australian reference range for patients with Parkinson’s disease and healthy controls with F-DOPA Positron Emission Tomography.

Establishing an Australian reference range for striatal binding in patients with Parkinson’s disease and healthy controls with 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12618000386235

Enrollment

Registered

2018-03-15

Start date

2018-03-20

Completion date

2020-03-10

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We propose to perform F-DOPA PET scans in 10 healthy volunteers and 20 participants with typical features of Parkinson’s disease (PD). Each will undergo an F-DOPA PET/CT scan. The healthy participants will also undergo an MRI scan to identify brain structures. Analysis of these scans will allow us to estimate how sensitive this PET scan is in discriminating between Parkinson’s disease and healthy people with no evidence of Parkinson’s disease. The collected data will assist in establishing Australian reference ranges which will assist in future analysis of these PET scans for patients with Parkinson’s disease.

Interventions

We propose to perform F-DOPA Positron Emission Tomography (PET) scans in 20 participants with typical clinical features of Parkinson’s disease (PD). Images will be compared to their standard care Magnetic Resonance Imaging (MRI) scans to identify brain structures. Previous MRI scans, performed within the last 12 months, will be selected for comparison to PET scans. All participants will be monitored for the duration of the PET scan appointment (approximately 4 hours). No additional follow-up wi

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Parkinson's disease: based on the UK Brain bank clinical criteria and a Hoehn and Yahr score of 2.5 or less (early PD) or 3.0 or more (late PD). Normal controls: aged matched individuals with no historical or clinical evidence of any neurological disorder. Greater than 18 years of age Able to undertake PET imaging Able to provide written informed consent

Exclusion criteria

Pregnancy Less than 18 years of age Medical contraindication to PET or MRI imaging Patients with concurrent psychiatric disorders, signs of severe cognitive deterioration and severe cardiovascular comorbidity. Cognitive impairment considered to impair the ability to give written informed consent in the opinion of the treating clinician

Outcome results